Literature DB >> 18445350

Latent (slowly progressing) autoimmune diabetes in adults.

Jochen Seissler1.   

Abstract

About 10% of patients with the clinical presentation of type 2 diabetes suffer from an autoimmune form of diabetes associated with a rapid decline of residual beta-cell mass and subsequent development of insulin dependency. In this condition, called latent autoimmune diabetes in adults (LADA), there are clinical and metabolic features intermediate between type 1 and type 2 diabetes. Recent studies provide novel information on the immune markers associated with progressive beta-cell loss in LADA patients. However, LADA pathogenesis is still poorly understood; further studies are needed to establish general recommendation for preventing and treating this subtype of autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18445350     DOI: 10.1007/s11892-008-0018-x

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  50 in total

1.  Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA).

Authors:  A Carlsson; G Sundkvist; L Groop; T Tuomi
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  Characterization of preparations of GAD65, proinsulin, and the islet tyrosine phosphatase IA-2 for use in detection of autoreactive T-cells in type 1 diabetes: report of phase II of the Second International Immunology of Diabetes Society Workshop for Standardization of T-cell assays in type 1 diabetes.

Authors:  M Peakman; T I Tree; J Endl; P van Endert; M A Atkinson; B O Roep
Journal:  Diabetes       Date:  2001-08       Impact factor: 9.461

3.  An association analysis of the HLA gene region in latent autoimmune diabetes in adults.

Authors:  M Desai; E Zeggini; V A Horton; K R Owen; A T Hattersley; J C Levy; M Walker; K M Gillespie; P J Bingley; G A Hitman; R R Holman; M I McCarthy; A Clark
Journal:  Diabetologia       Date:  2006-12-02       Impact factor: 10.122

4.  Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe.

Authors:  Bernard Zinman; Steven E Kahn; Steven M Haffner; M Colleen O'Neill; Mark A Heise; Martin I Freed
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

Review 5.  Immunomodulation for the prevention of SPIDDM and LADA.

Authors:  P Pozzilli; C Guglielmi
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

6.  Association of amino-terminal-specific antiglutamate decarboxylase (GAD65) autoantibodies with beta-cell functional reserve and a milder clinical phenotype in patients with GAD65 antibodies and ketosis-prone diabetes mellitus.

Authors:  Christiane S Hampe; Ramaswami Nalini; Mario R Maldonado; Tyler R Hall; Gilberto Garza; Dinakar Iyer; Ashok Balasubramanyam
Journal:  J Clin Endocrinol Metab       Date:  2006-11-07       Impact factor: 5.958

7.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

8.  T-cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta-cell lesions in phenotypic type 2 diabetes.

Authors:  Amit Goel; Harvey Chiu; Jamie Felton; Jerry P Palmer; Barbara Brooks-Worrell
Journal:  Diabetes       Date:  2007-05-01       Impact factor: 9.461

9.  Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).

Authors:  Zhiguang Zhou; Xia Li; Gan Huang; Jian Peng; Lin Yang; Xiang Yan; Jianping Wang
Journal:  Diabetes Metab Res Rev       Date:  2005 Mar-Apr       Impact factor: 4.876

10.  Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive type 1 diabetes.

Authors:  Tetsuro Kobayashi; Shoichiro Tanaka; Minoru Okubo; Koji Nakanishi; Toshio Murase; Ake Lernmark
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

View more
  7 in total

1.  Surgery for diabetes at lower BMI: some caution.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2008-08-30       Impact factor: 4.129

2.  Update: Why diabetes does not resolve in some patients after bariatric surgery.

Authors:  Mervyn Deitel
Journal:  Obes Surg       Date:  2011-06       Impact factor: 4.129

3.  [Update on type 1 diabetes].

Authors:  I Heukamp; C Then; A Lechner; J Seissler
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

4.  β-cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up.

Authors:  Maria Thunander; Hlin Thorgeirsson; Carina Törn; Christer Petersson; Mona Landin-Olsson
Journal:  Eur J Endocrinol       Date:  2010-11-18       Impact factor: 6.664

5.  Diabetic ketoacidosis as first presentation of latent autoimmune diabetes in adult.

Authors:  Omar Nadhem; Essam Nakhla; Roger D Smalligan
Journal:  Case Rep Med       Date:  2015-03-05

Review 6.  Bariatric Surgery and Type 1 Diabetes: Unanswered Questions.

Authors:  Emmanouil Korakas; Aikaterini Kountouri; Athanasios Raptis; Alexander Kokkinos; Vaia Lambadiari
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-18       Impact factor: 5.555

Review 7.  C-peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective.

Authors:  Ernesto Maddaloni; Geremia B Bolli; Brian M Frier; Randie R Little; Richard D Leslie; Paolo Pozzilli; Raffaela Buzzetti
Journal:  Diabetes Obes Metab       Date:  2022-06-28       Impact factor: 6.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.